Anecortave Acetate Risk-Reduction Trial (AART) | NCT00307398 | Trialant

Anecortave Acetate Risk-Reduction Trial (AART) | NCT00307398 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
AL-3789	Experimental	One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.	Drug: Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Anecortave Acetate Vehicle	Sham Comparator	One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.	Other: Anecortave Acetate Vehicle

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg	Drug	One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Proportion of patients with sight-threatening choroidal neovascularization (ST-CNV) in the study eye at Month 48	ST-CNV is defined as CNV or a portion of CNV within 2500 microns of the foveal center, as evidenced by digital angiography at the clinical site.	Month 48

Contacts/Locations Module